ESTEVE’s Post

MORSE Consulting Inc.'s Sang Mi Lee, MBA, BSc Phm, RPh is honoured to be presenting at the 2023 Fall Canadian Organization for Rare Disorders (CORD) Conference, where she will be joining an esteemed session entitled “Canadian Integrated Lifecycle Drug Development, Access, and Management Model for Rare Disease Populations.” Sang Mi's presentation on the morning of November 30th focuses on the "Challenges and Success with Win-Win Negotiations." She will share data-driven insights on drugs for rare diseases and best practices for innovative agreements and pCPA negotiations. Additionally, Sang Mi will contribute to discussions on "Negotiations for Accelerated & Sustainable Access” in the afternoon amongst a highly knowledgeable panel of experts from patient organizations, the public sector, industry and consulting. Using case studies, they will try to answer the question: How can we accelerate access to effective and cost-effective innovative therapies to reach a mutually beneficial agreement for all parties, including the patients? Learn more about CORD here: https://ow.ly/elZZ50Qb6mN Source: https://ow.ly/GGmn50QbAUv #CORDConference #RareDiseases #pCPANegotiations #InnovativeAgreementss

In this update, #SyenzaTeam covers how to pay for universal access to rare disease medicines. 1️⃣ The UK's innovative pricing strategies and managed access agreements aim to balance cost and care effectiveness. 2️⃣ The UK has shifted its pricing strategy to include severity modifiers, allowing for higher payment thresholds for severe conditions. 3️⃣ Managed access agreements facilitate real-world evidence collection, yet burden healthcare professionals with data management tasks. 📊 Are we truly making strides towards fair drug pricing, or merely patching a widening gap? #pharmaceuticalindustry #marketaccess #heor #medicaldevices #healtheconomics #outcomesresearch #hta

This Parkinson's Disease Awareness Month 🌷, join Vivpro Corp as we illuminate the landscape of regulatory intelligence in this critical area. With the #RIA platform, you can: 1️⃣ Effortlessly search through a multitude of approved products and clinical trials with one intuitive workflow. 2️⃣ Search any indication to discover products that have received "expedited pathways." 3️⃣ Quickly replicate a competitor's Clinical Development Plan and see which trials may have led to approval with RIA's CDP module! 4️⃣ RIA offers quick access to vital Clinical Trials Data. Stay at the forefront of the ever-evolving drug development landscape. ➡ 📞 Schedule a call with us to learn more. https://vivpro.ai/contact #ParkinsonsDisease #ParkinsonsAwareness #RegulatoryIntelligence #DrugDevelopment #WisdomWednesday #Vivpro #MorePowerToYou

☑️ Early diagnosis and treatment can prevent complications and enable people to live as normal a life as possible. ☑️ Early diagnosis contributes greatly to improved quality of life and care for people with PI ☑️ Patient access to care and appropriate treatment can help prevent serious and life-threatening illnesses in people with PI With this in mind, the video campaign “AFFIANCO” ("walk together”) narrated the extraordinary and touching experiences of five patients and their referring doctors, who, from a certain moment of their existence, began to "walk together" in the difficult battle against Primary Immunodeficiencies (PID), rare diseases of the immune system. The initiative was conceived and developed by the Associazione Nazionale Immunodeficienze Primitive - AIP O.d.V. (Italian Association of Primary Immunodeficiencies - AIP O.d.V.) and supported by Kedrion with an unconditional grant. 🎥 Watch the stories: https://lnkd.in/dPyhpUYE [TIP: Click on the automatic subtitles on youtube for more languages] #WorldPIWeek #WorldPIWeek2024 #PIDs #PrimaryImmunodeficiency #RaiseAwareness

The Inflation Reduction Act or #IRA will bring about foundational changes for #raredisease patients, some unequivocally good while for others the jury is still out. The stakes are high for patients, families, and rare disease companies, which is why evidence-based policies are key. Great new article in BioCentury Inc. explaining the different viewpoints - and why we are focused on highly targeted, near-term technical fixes to mitigate immediate unintended impacts on rare disease #research and R&D #pipelines. https://lnkd.in/dQU8pAEc

Today, February 29, is Rare Disease Day. Did you know over 95% of rare diseases lack approved therapy? It’s a staggering reality for millions of patients. But, there’s hope.   Join Molly Borchardt, PharmD, Senior Director, Access Experience Team at PRECISIONvalue, as she shares crucial insights to elevate your access strategy. From navigating the complexities of rare disease management to engaging with payers early and demonstrating innovation value, you’ll gain actionable guidance to make a difference.   Ready to take the next step? Download now to unlock the potential of your rare disease initiatives and empower patients waiting for life-changing therapies. #rarediseaseday #accessforall  

OptumRx will ‘…launch Weight Engage, aimed at offering a flexible solution to the high cost GLP-1s, to employer sponsors…’ in January 2024. The program ‘…offers weight management and cardio metabolic disease solutions to support better health outcomes and manage consumer drug spending…’ with a focus upon ‘…coverage of GLP-1s for weight loss purposes.’ The approach is certainly to address GLP-1 costs, without compelling data today for a valid return on investment. https://lnkd.in/eFGD_qRY

The Rise in awareness about early-stage disease diagnosis and government screening programs to lower the incidence rate and mortality are anticipated to burgeon the growth of the #point of #care #diagnostics market over the forecast years. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞: (https://lnkd.in/gKfCzywY) Abbott, Koninklijke Kentalis, BD, Mologico GmbH, Johnson & Johnson, Sinocare Inc., Roche Diagnostics UK & Ireland, Nova Biomedical, Instrumentation Limited, Palakkad, AccuBioTech Co., Ltd., Alpha Laboratories Ltd., EKF Diagnostics, Spectral Medical Inc., OraSure Technologies, SEKISUI Diagnostics, Trinity Biotech, QuidelOrtho, Trividia Health, Inc. , Nova Biomedical, Werfen, Siemens Healthcare FZ LLC , bioMérieux #marketanalysis #marketgrowth #marketdata #marketsize #marketshare #markettrends #marketreport #marketoutlook #marketoverview #drivers #marketresearchreport #marketsegmentation #marketsummary #restraints #researchanddevelopment #researchmethods #researchreport #marketdemand

The latest feature in #TheMicrobiologist reveals the incredible story of how a global network was set up for coordinating the transfer of therapeutic phage to patients and doctors around the world. From finding participants to setting up diagnostics, production and QC systems, discover how these networks are helping to deliver phage when antibiotics fail. #WAAW #AMR https://lnkd.in/epts9D8b